Sofosbuvir, a significant paradigm change in hcv treatment

Journal of Clinical and Translational Hepatology

Volumn 3, Issue 1, 2015, Pages 27-35

  McQuaid, Thomas ^a   Savini, Carolyn ^b   Seyedkazemi, Star ^c  

^a Gilead Sciences   (United States)

^b Gilead Sciences   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

Direct acting antivirals; Ledipasvir; Sofosbuvir

Indexed keywords

EID: 84955473433     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00041     Document Type: Review

References (27)

1. Chae HB, Park SM, Youn SJ. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. Scientific World Journal 2013;2013:704912. doi: 10.1155/2013/704912.
2. Meanwell NA, Watkins WJ. Introduction to Hepatitis C Virus (HCV) Therapies Special Thematic Issue. J Med Chem 2014;57:1625–1626. doi: 10.1021/jm5000936.
3. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 2014; 7:131–140. doi: 10.1177/1756283X13515825.
4. Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int 2013;33(Suppl):85–92. doi: 10.1111/liv.12068.
5. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013;58:428–438. doi: 10.1002/hep.26371.
6. Mosley RT, Edwards TE, Murakami E, Lam AM, Grice RL, Du J, et al. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol 2012;86:6503–6511. doi: 10.1128/JVI.00386-12.
7. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56:3359–3368. doi: 10.1128/AAC.00054-12.
8. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al. Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53:7202–7218. doi: 10.1021/jm100863x.
9. De Clercq E. Dancing with chemical formulae of antivirals: A panoramic view (Part 2). Biochem pharmacol 2013;86:1397–1410. doi: 10.1016/j.bcp.2013.09.010.
10. Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733–3742. doi: 10.2174/09298673113209990178.
11. http://www.sovaldi.com/, accessed December 10, 2014.
12. Kirby B, Gordi T, Symonds W, Mathias A. Population Pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected adult subjects. Hepatology 2013,58:746A–747A.
13. Mathias A. Clinical Pharmacology Workshop in HIV (and HCV) PResentations on New DAA’s oral HCV drugs in phase 3 development now. Proceedings 14th International Workshop on Clinical Pharmacology of HIV Thearpy, 2013; Amsterdam, Netherlands.
14. Rodriguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther 2013;11: 1269–1279. doi: 10.1586/14787210.2013.855126.
15. Lawitz EJ. The effect of Hepatic Impairment on the Pharmacokinetics and anti-viral activity of PSI-7977 in Hepatitis C infected subjects treated for seven days. European Association for the Study of Liver Disease, 2012; Barcelona, Spain.
16. Cornpropst M, Denning J, Clemons D, Marbury T, Alcorn H. The Effect of Renal Impairment and End Stage Renal Disease on The Single-Dose pharmacoki-netics of PSI-7977. J Hepatol 2012;56:S433. doi: 10.1016/S0168-8278 (12)61113-1.
17. Cornpropst M. PSI-7977 Has no effect on QTcF intervals at Therapeutic or Supratherapeutic Doses. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2011; San Francisco, CA, USA.
18. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;369:678–679. doi: 10.1056/NEJMc1307641.
19. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804– 811. doi: 10.1001/jama.2013.109309.
20. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. N Engl J Med 2013;368:1867–1877. doi: 10.1056/NEJMoa1214854.
21. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370: 1993–2001. doi: 10.1056/NEJMoa1316145.
22. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312:353–361. doi: 10.1001/jama.2014.7734.
23. Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, Shen G, Symonds B, McHutchison J, et al. Sofosbuvir and Peginterferon alfa-2a/Ribavirin Treatment of naive Genotype 1–4 infected patients that are co-infected with HIV. Conference Reports for NATAP, ID Week, 2013; San Francisco, CA, USA.
24. http://www.harvoni.com/, accessed December 10, 2014.
25. Afdhal N, Reddy KR, Nelson DR,, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–1493. doi: 10.1056/NEJMoa1316366.
26. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370: 1889–1898. doi: 10.1056/NEJMoa1402454.
27. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888. doi: 10.1056/NEJMoa1402355